Anika Therapeutics (NASDAQ:ANIK) Full Year 2022 Results

Key Financial Results

  • Revenue: US$156.2m (up 5.7% from FY 2021).

  • Net loss: US$14.9m (down by 459% from US$4.13m profit in FY 2021).

  • US$1.02 loss per share (down from US$0.29 profit in FY 2021).



All figures shown in the chart above are for the trailing 12 month (TTM) period

Anika Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company’s shares are up 2.9% from a week ago.

Balance Sheet Analysis

While it’s very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. See our latest analysis on Anika Therapeutics’ balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here